310 Cell-Penetrating Peptides Found Hidden in the SARS-CoV-2 Virus Genome

Computational screening identified 310 cell-penetrating peptide sequences in the SARS-CoV-2 proteome, with 94% predicted non-toxic and potential as drug delivery tools.

Hemmati, Shiva et al.·Infection·2020·Preliminary EvidenceComputational/Bioinformatics
RPEP-04849Computational/BioinformaticsPreliminary Evidence2020RETHINKTHC RESEARCH DATABASErethinkthc.com/research

Quick Facts

Study Type
Computational/Bioinformatics
Evidence
Preliminary Evidence
Sample
SARS-CoV-2 proteome (computational analysis)
Participants
SARS-CoV-2 proteome (computational analysis)

What This Study Found

A systematic computational screen of the SARS-CoV-2 proteome identified 310 sequences with cell-penetrating peptide (CPP) characteristics. These SCV2-CPPs spanned regions involved in replication, protein-nucleotide interaction, protein-protein interaction, and complex stabilization.

Safety and practicality analysis: 94.3% were predicted non-toxic. 38% were neither antigenic nor allergenic, important for therapeutic use. 36.7% resisted all four major protease families, meaning they could survive in biological fluids.

Structural analysis: about one-third had sufficient helix or sheet structure for efficient cellular uptake. Among helical CPPs, 44.3% were predicted lipid-binding, important for membrane interaction.

The top candidates for drug delivery were SCV2-CPP118, 119, 122, and 129, all from NSP12 (RNA-dependent RNA polymerase). Cysteine-rich CPPs from the helicase (NSP13) could potentially form cyclic structures in endosomes for better release.

Beyond delivery: 59.6% had predicted antibacterial activity, 29.6% antiviral, 32.3% antifungal, 63.6% immunomodulatory, and 21.9% anticancer properties.

Key Numbers

310 CPPs; 94.3% non-toxic; 38% non-antigenic; 36.7% protease-resistant; 4 top candidates from NSP12

How They Did This

Computational study. The entire SARS-CoV-2 proteome was screened using cell-penetrating peptide prediction algorithms. Identified CPPs were analyzed for toxicity, antigenicity, allergenicity, protease resistance, secondary structure, lipid-binding potential, and bioactive properties. Ten experimentally validated viral CPPs from other viruses were used as positive controls to validate the screening pipeline.

Why This Research Matters

Viruses are nature's experts at getting inside cells. Mining viral proteomes for cell-penetrating peptides converts a pathogen into a source of drug delivery tools. The SARS-CoV-2 proteome had not been screened before. Some identified peptides could serve as delivery vehicles; others might be therapeutic themselves.

The Bigger Picture

Viruses are nature's experts at entering cells. Mining viral genomes for cell-penetrating peptides converts pathogens into sources of drug delivery tools. This approach could yield delivery vectors with evolved cell-entry capabilities.

What This Study Doesn't Tell Us

Entirely computational. None of the 310 peptides have been synthesized or experimentally tested for cell penetration, toxicity, or bioactivity. Prediction algorithms have significant false-positive rates. The four top candidates need laboratory validation. In silico protease resistance predictions do not always match real-world degradation.

Questions This Raises

  • ?Do any of these 310 predicted CPPs actually penetrate cells when synthesized?
  • ?Could using virus-derived peptides trigger unwanted immune responses?
  • ?Are CPPs from other virus families equally promising?

Trust & Context

Key Stat:
310 CPPs discovered in the SARS-CoV-2 proteome, with 94% predicted safe for drug delivery applications
Evidence Grade:
Preliminary evidence — entirely computational. None of the predicted peptides have been experimentally validated for cell penetration or safety.
Study Age:
Published in 2020 during the COVID-19 pandemic. Experimental validation of these candidates may have followed.
Original Title:
Decoding the proteome of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) for cell-penetrating peptides involved in pathogenesis or applicable as drug delivery vectors.
Published In:
Infection, genetics and evolution : journal of molecular epidemiology and evolutionary genetics in infectious diseases, 85, 104474 (2020)
Database ID:
RPEP-04849

Evidence Hierarchy

Meta-Analysis / Systematic Review
Randomized Controlled Trial
Cohort / Case-Control
Cross-Sectional / ObservationalSnapshot without intervening
This study
Case Report / Animal Study
What do these levels mean? →

Frequently Asked Questions

Can virus proteins be safely used as drug delivery tools?

Potentially. The peptide sequences are short fragments, not whole virus proteins. If they can penetrate cells without triggering immune reactions, they could become useful delivery vehicles. But this needs experimental confirmation.

Why search a virus for cell-penetrating peptides?

Viruses evolved specifically to enter cells efficiently. Their proteins contain sequences optimized by evolution for membrane crossing — exactly the capability needed for drug delivery.

Read More on RethinkPeptides

Cite This Study

RPEP-04849·https://rethinkpeptides.com/research/RPEP-04849

APA

Hemmati, Shiva; Behzadipour, Yasaman; Haddad, Mahdi. (2020). Decoding the proteome of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) for cell-penetrating peptides involved in pathogenesis or applicable as drug delivery vectors.. Infection, genetics and evolution : journal of molecular epidemiology and evolutionary genetics in infectious diseases, 85, 104474. https://doi.org/10.1016/j.meegid.2020.104474

MLA

Hemmati, Shiva, et al. "Decoding the proteome of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) for cell-penetrating peptides involved in pathogenesis or applicable as drug delivery vectors.." Infection, 2020. https://doi.org/10.1016/j.meegid.2020.104474

RethinkPeptides

RethinkPeptides Research Database. "Decoding the proteome of severe acute respiratory syndrome c..." RPEP-04849. Retrieved from https://rethinkpeptides.com/research/hemmati-2020-decoding-the-proteome-of

Access the Original Study

Study data sourced from PubMed, a service of the U.S. National Library of Medicine, National Institutes of Health.

This study breakdown was produced by the RethinkPeptides research team. We analyze and report published research findings without making health recommendations. All interpretations are based solely on the published abstract and study data.